Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  221.27
-1.29 (-0.58%)
AAPL  271.84
-2.77 (-1.01%)
AMD  198.11
-11.06 (-5.29%)
BAC  54.55
-0.26 (-0.47%)
GOOG  298.06
-9.67 (-3.14%)
META  649.50
-7.65 (-1.16%)
MSFT  476.12
-0.27 (-0.06%)
NVDA  170.94
-6.78 (-3.81%)
ORCL  178.46
-10.19 (-5.40%)
TSLA  467.26
-22.62 (-4.62%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.